Know a great AI tool or AI news source? Submit it to AiByts
Rosalind1 min read

OpenAI acquires Orchestra Bio to build AI agents that speed up drug development

OpenAI is acquiring startup Orchestra Bio and plans to merge it with its life sciences AI platform Rosalind. The goal is to build AI agents that help pharma teams coordinate drug development, from tracking trials to spotting problems.

By Manuel UthThe Decoder
OpenAI acquires Orchestra Bio to build AI agents that speed up drug development

Read the full story

Originally published by The Decoder on Oct 21, 2026.

Read on The Decoder(opens in a new tab)

Comments

Sign in to join the discussion.

No comments yet — be the first to share your thoughts.